CorMedix First Ever Profitable Quarter with $39.1M Revenue, Raises Guidance

CorMedix Inc. (CRMD) reported strong Q1 2025 financial results with net revenue of $39.1 million and net income of $20.6 million ($0.32 per share), compared to a net loss in Q1 2024. The company achieved adjusted EBITDA of $23.6 million and positive cash flow from operations of $19.7 million. DefenCath sales drove performance, particularly in outpatient dialysis. The inpatient sales team is now fully operational, with institutional shipments doubling over three months. CorMedix commenced a Phase 3 study for reducing CLABSIs in TPN patients. The company expects to hit the high end of its H1 2025 sales guidance ($62-70 million) and reported cash and short-term investments of $77.5 million, sufficient for at least 12 months of operations.

https://www.stocktitan.net/news/CRMD/cor-medix-inc-reports-first-quarter-2025-financial-results-and-8cbk7pwcffhh.html